Assignee
IRONWOOD PHARMACEUTICALS INC
US·21 granted patents·102 pending applications·247 citations·filing 2005–2024
Top patents by PatentIndex Score
123 records- 0196US7494979B2Method for treating congestive heart failure and other disordersIRONWOOD PHARMACEUTICALS INC·Filed 2005·Granted Feb 24, 2009·38 cites·14 claims
- 0295US7910546B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·29 cites·28 claims
- 0395US7745409B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2007·Granted Jun 29, 2010·29 cites·7 claims
- 0495US7704947B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2007·Granted Apr 27, 2010·29 cites·16 claims
- 0594US9586937B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Mar 7, 2017·13 cites·2 claims
- 0693US9481689B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Nov 1, 2016·16 cites·2 claims
- 0793US7772188B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2005·Granted Aug 10, 2010·31 cites·10 claims
- 0892US9840536B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2015·Granted Dec 12, 2017·8 cites·4 claims
- 0991US10183021B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Jan 22, 2019·8 cites·9 claims
- 1091US9725453B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·7 cites·2 claims
- 1191US9139564B22-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2012·Granted Sep 22, 2015·15 cites·6 claims
- 1287US9309235B2SGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Apr 12, 2016·12 cites·25 claims
- 1385US2023346881A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1485US2024075094A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1585US2023340025A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1684US2023248758A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1783US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1883US2024115656A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1981US8946158B2Treatments of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Feb 3, 2015·5 cites·35 claims
- 2081US2023263854A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2180US10047095B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2015·Granted Aug 14, 2018·4 cites·26 claims
- 2279US2025073301A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2379US2022227812A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2479US2023272007A1Treatments for gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2579US2022233635A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2678US10675325B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jun 9, 2020·0 cites·18 claims
- 2778US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2878US2022133777A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2976US2022031802A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3075US10702576B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jul 7, 2020·0 cites·20 claims
- 3175US2021388026A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3275US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3375US2020113931A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3475US2023398173A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3575US2021290662A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3675US2011129433A1Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3775US2022111001A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3874US9540380B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·1 cites·1 claims
- 3974US2022370367A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4073US2023142270A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4172US10618938B2Compositions for colon cleansing and the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Apr 14, 2020·1 cites·30 claims
- 4271US7960544B2Useful indole compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2006·Granted Jun 14, 2011·1 cites·34 claims
- 4371US2022110876A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4471US2020283479A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4570US2022119452A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4670US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4768US2020009216A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4868US2021267903A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4967US2022202725A1Modified or Targeted Release Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5067US2024199697A1Compositions for Colon Cleansing and the Treatment of Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 123 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IRONWOOD PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →